epinephrine + levosimendan

Epinephrine + levosimendan is a combination of two pharmacological agents used experimentally and in critical care settings for cardiovascular support, particularly during cardiac arrest, severe heart failure, or situations requiring enhanced inotropic support. Epinephrine (adrenaline) is a catecholamine that acts as an agonist at alpha- and beta-adrenergic receptors, leading to increased heart rate, myocardial contractility, vasoconstriction, and bronchodilation. Levosimendan is an inodilator that increases cardiac contractility primarily by sensitizing cardiac troponin C to calcium (calcium sensitizer), while also causing vasodilation through the opening of adenosine triphosphate–sensitive potassium channels in vascular smooth muscle cells and providing cardioprotective effects via mitochondrial KATP channel activation. The combination has been shown in preclinical studies to improve survival rates after cardiac arrest compared to epinephrine alone and may reduce lung damage and overall catecholamine requirements[1][2][3]. This synergistic effect appears especially beneficial under conditions such as acidosis or when conventional therapy is insufficient.